PureTech Health
Jump to navigation
Jump to search
| Company type | Public |
|---|---|
| Headquarters | Boston, United States |
Key people | Christopher Viehbacher (Chairman) Daphne Zohar (CEO) |
| Products | Medicines |
| Website | puretechhealth |
PureTech Health is a biotech company listed on the London Stock Exchange and included in the FTSE 250 Index. It was founded in 2005 by Daphne Zohar.[2] PureTech Health develops medicines to treat serious diseases. It has subsidiary companies focused on various therapeutic areas, including neuropsychiatric disorders, weight management, cognitive disorders, autoimmune diseases, and inflammatory diseases.[3] They also have their own pipeline of therapeutics in immunology, lymphatics, and oncology.[4]
References
- ↑ 1.0 1.1 1.2 Annual Results 2022PureTech Health. Retrieved 28 April 2023.
- ↑ PureTech's long view on biopharma (26 August 2015)Boston Globe. Retrieved 16 August 2019.
- ↑ PureTech Health affiliate Vedanta Biosciences awarded $5.8m grant (5 December 2019)Sharecast. Retrieved 14 December 2019.
- ↑ PureTech Licenses Glyph Lymphatic Technology (29 August 2017)FT. Retrieved 14 December 2019.